EFTA00718701.pdf

From: Jeffrey Epstein <jeffreyepsteinorg®gmail.com> To: Jeffrey Epstein <[email protected]>, Cecile de Jongh Subject: Fwd: Re - Ovarian Cancer Date: Thu, 21 Jun 2012 15:05:34 +0000 Attachments: Autelitano_et_al_2012-JTM.PDF; Interim OvPlex-Clinic A-Feb 2012.pdf As a result of my recent Ovarian Cancer article. Forwarded message From: Nick Gatsios Date: Wed, Jun 20, 2012 at 7:52 PM Subject: Re - Ovarian Cancer To: jeffreyepsteinorg <[email protected]> Cc: Rochelle Lade Dear Jeffery, I have just read the article circulated via PR Newswire with some interest and I thought that you might find what we have developed of interest. Attached is our latest data manuscript as well as some additional data that suggests OvPkx"' is best in class in diagnosing symptomatic women earlier and discriminating benign mass from tumours. At present we have our product distributed in the UK, Singapore, Malaysia and Australia and about to launch into India and Spain. I feel that it would be mutually beneficial to establish a telco to discuss our desire to move the company to the US and drive the FDA path. I look forward to hearing back from you soon. Kind Regards Nick Gatsios Managing Director FlealthLinx Limited 576 Swan Street EFTA00718701 Richmond Vic 3121 P. f. m. EFTA00718702